paget's%20bone%20disease
PAGET'S BONE DISEASE
Paget's bone disease, also known as osteitis deformans, is characterized by a significant increase in bone resorption and turnover in localized parts of the skeleton causing enlargement and thickening of the bone that is disordered and architecturally unstable.
The prevalence increases with age, with men and women affected equally.
Genetic factors and/or viral infection may play a role in the etiology.
May affect one bone (monostotic) or several bones (polyostotic).
By decreasing frequency, involved bones may include pelvic bone and sacrum, spine, skull and femur, tibia, humeri and clavicles.

Definition

  • Paget’s bone disease, also known as osteitis deformans, is characterized by a significant increase in bone resorption & turnover in localized parts of the skeleton causing enlargement & thickening of the bone that is disordered & architecturally unstable

Signs and Symptoms

Signs & Symptoms

  • Asymptomatic for a long period of time before signs & symptoms occur
  • Bone or joint pain
  • Bone enlargement or bone deformity (eg skull enlargement, bowing of long bones)
    • Pelvis & tibia are one of the most commonly affected bones

Risk Factors

  • Prevalence increases w/ age, w/ men & women affected equally
  • Genetic factors &/or viral infection may play a role in the etiology
  • May affect one bone (monostotic) or several bones (polyostotic)
  • By decreasing frequency, involved bones may include pelvic bone & sacrum, spine, skull & femur, tibia, humeri & clavicles
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2015
BLACKMORES VITAMIN D3 – Vitamin D3 1,000 IU Capsules
15 Dec 2016
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Kavitha G. Shekar, 21 Jun 2016

The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.

31 Jul 2017
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.